Premium
Molecular signalling pathways in canine gliomas
Author(s) -
Boudreau C. E.,
York D.,
Higgins R. J.,
LeCouteur R. A.,
Dickinson P. J.
Publication year - 2017
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12147
Subject(s) - glioma , pten , cancer research , pi3k/akt/mtor pathway , mdm2 , signalling pathways , protein kinase b , biology , blot , signal transduction , pathology , cell culture , medicine , microbiology and biotechnology , gene , genetics
In this study, we determined the expression of key signalling pathway proteins TP53 , MDM2 , P21 , AKT , PTEN , RB1 , P16 , MTOR and MAPK in canine gliomas using western blotting. Protein expression was defined in three canine astrocytic glioma cell lines treated with CCNU , temozolamide or CPT ‐11 and was further evaluated in 22 spontaneous gliomas including high and low grade astrocytomas, high grade oligodendrogliomas and mixed oligoastrocytomas. Response to chemotherapeutic agents and cell survival were similar to that reported in human glioma cell lines. Alterations in expression of key human gliomagenesis pathway proteins were common in canine glioma tumour samples and segregated between oligodendroglial and astrocytic tumour types for some pathways. Both similarities and differences in protein expression were defined for canine gliomas compared to those reported in human tumour counterparts. The findings may inform more defined assessment of specific signalling pathways for targeted therapy of canine gliomas.